ProQR Therapeutics (PRQR) Non-Current Deffered Revenue (2021 - 2024)
Historic Non-Current Deffered Revenue for ProQR Therapeutics (PRQR) over the last 4 years, with Q4 2024 value amounting to $31.4 million.
- ProQR Therapeutics' Non-Current Deffered Revenue fell 3382.81% to $31.4 million in Q4 2024 from the same period last year, while for Dec 2024 it was $31.4 million, marking a year-over-year decrease of 3382.81%. This contributed to the annual value of $31.9 million for FY2024, which is 3333.51% down from last year.
- ProQR Therapeutics' Non-Current Deffered Revenue amounted to $31.4 million in Q4 2024, which was down 3382.81% from $47.5 million recorded in Q4 2023.
- In the past 5 years, ProQR Therapeutics' Non-Current Deffered Revenue registered a high of $66.9 million during Q4 2022, and its lowest value of $16.8 million during Q4 2021.
- In the last 4 years, ProQR Therapeutics' Non-Current Deffered Revenue had a median value of $39.5 million in 2024 and averaged $40.7 million.
- In the last 5 years, ProQR Therapeutics' Non-Current Deffered Revenue soared by 29815.23% in 2022 and then plummeted by 3382.81% in 2024.
- Quarter analysis of 4 years shows ProQR Therapeutics' Non-Current Deffered Revenue stood at $16.8 million in 2021, then soared by 298.15% to $66.9 million in 2022, then fell by 28.96% to $47.5 million in 2023, then tumbled by 33.83% to $31.4 million in 2024.
- Its Non-Current Deffered Revenue stands at $31.4 million for Q4 2024, versus $47.5 million for Q4 2023 and $66.9 million for Q4 2022.